Search This Blog

Thursday, September 1, 2022

Wuhan Lab Linked to COVID-19 Discovers Novel Animal Virus

 Researchers at the Wuhan Institute of Virology (WIV), which is possibly linked to the origins of COVID-19, reported the discovery of a novel DNA virus in animals in the journal Virologica Sinica

The scientists analyzed tissue specimens from 232 animals, including 226 rodents, five shrews and one hedgehog, collected from five counties in Kenya and tested for DNA viruses. The viruses belong to seven viral families, and the researchers utilized PCR to run the tests. They noted that although surveillance programs focus more on RNA viruses - such as SARS-COV-2, the virus that causes COVID-19 - less is known about DNA viruses. 

The researchers identified a range of DNA sequences associated with adenoviruses, adeno-associated viruses, herpesviruses and polyomaviruses. Conducting phylogenetic analyses, they found most were distinct from previously described viruses. They also noted this was the first report of a full-length genomic characterization of a polyomavirus in Lemniscomys species.

The virus was dubbed LsPyV KY187 and “has less than 60% amino acid sequence identity to the most related Glis glis polyomavirus 1 and Scirus carolinensis polyomavirus 1 in both large and small T-antigen proteins, and thus can be putatively allocated to a novel species within Betapolyomavirus,” the authors wrote. 

Viruses Not Known to be Transmissible to Humans

“The results of this study are important for our understanding of viruses and their evolution in non-human animals,” Sean Beckmann, Ph.D., assistant professor of biology at Stetson University in Florida, who was not involved in the study, told BioSpace. “However, these findings should be taken in context. None of the viruses identified, or the novel viruses, are known to be transmissible to humans, and the authors don’t make any claims about their pathogenicity.” 

The authors emphasized that the research supports the need to continue studying rodent-borne viruses in East Africa. In addition, because the new virus does not appear to be closely related to any known pathogens, its effect on humans is “unclear and needs to be further assessed,” the researchers stated. 

Beckmann was equally cautious. “These findings are still valuable and important, but they shouldn’t be a cause for alarm that a bunch of new human pathogens have been found. Among the viruses that were identified, we don’t have any evidence of rodent to human transmission within those groups," he said. 

WIV and its Link to COVID-19 Transmission Theories 

The WIV is a leading research institute that focuses on viruses, but its possible association with the origins of COVID-19 has increased scrutiny of its operations.

There are two primary theories about the origin of COVID-19: the “lab-leak” theory and the “wet market” theory. The lab-leak theory argues the virus likely originated in bats, which were studied at the WIV, and then was accidentally released from the laboratory, possibly by an infected staffer. The wet market theory proposes that the virus originated in bats, moved to an intermediary animal at the Huanan Seafood Wholesale Market in Wuhan, and then to humans. The market is a few miles from the WIV. 

In addition to researchers at WIV, the Kenya study was conducted by investigators from the Chinese Academy of Sciences in Wuhan, China, the Mammalogy Section of the National Museums of Kenya, the Veterinary Services Department of the Kenya Wildlife Service and the Institute of Biotechnology Research, Jomo Kenyatta University of Science and Technology in Nairobi, Kenya.

The authors noted, “Emergence and re-emergence of infectious diseases of wildlife origin have led pre-emptive pathogen surveillances in animals to be a public health priority.” 

Beckmann concurred, telling BioSpace, “Since the emergence of COVID-19 (SARS-CoV-2), there has been increased attention and focus on the potential for other virus/bacteria/etc. to spill over from non-human animals to humans. This is long overdue, and these results do demonstrate the type of information we can gain."

https://www.biospace.com/article/wuhan-lab-potentially-linked-to-covid-19-discovers-novel-animal-virus-/

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"

 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing its side effects, is pleased to announce the Company's shares of common stock has commenced trading on The Nasdaq Capital Market under the ticker symbol "SHPH".


Historically, the major advances in radiation oncology have focused on improving technology to increase the amount of radiation that can be administered to a tumor without damaging adjacent, normal tissues. Examples of other such technologies include intensity modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and proton therapy – the backbones of state-of-the-art RT. All offer improvements in physical radiation dose shaping. The basic principle underlying the effectiveness of RT for curing cancers lies in the differential cancer cell kill achieved in tumors, as compared to the effects of RT on the normal surrounding tissues, which is achieved by delivery of highly conformal RT doses – in other words, delivery of high-dose to volumes that are shaped to conform to the target cancers while minimizing the dose to surrounding normal tissues. The treated volumes frequently include sensitive normal tissues, thereby limiting the magnitudes of the prescribed RT doses. We suggest that technological innovations to define tumor volumes and shape radiation delivery have reached an effectiveness plateau and that further improvements in RT outcomes will require pharmacological and immunological approaches to sensitize cancers, protect normal tissues and engage the immune system.

https://finance.yahoo.com/news/shuttle-pharmaceuticals-commences-trading-nasdaq-172000516.html

Celsion: Progress in DNA-based Vaccine Program with covid virus

 Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. Additional data from its completed proof-of-concept mouse challenge study confirms that a PLACCINE vaccine can produce robust levels of IgG, neutralizing antibodies, and T-cell responses.

The Company previously reported evidence of IgG, neutralizing antibody, and T-cell responses to its SARS-CoV-2 PLACCINE vaccines in normal mice. The additional data from its now completed mouse challenge study demonstrates the ability of the Company’s PLACCINE vaccine to protect a SARS-CoV-2 mouse model in a live viral challenge. In the study, mice were vaccinated with a PLACCINE vaccine expressing the SARS-CoV-2 spike antigen from the D614G variant or the Delta variant, or a combination vaccine expressing both the D614G and Delta spike variants. The vaccination was administered by intramuscular injection on Day 0 and Day 14, followed by challenge with live SARS-CoV-2 virus on Day 42. All three vaccines, including the single and dual antigen vaccines, were found to be safe and elicited IgG responses and inhibited the viral load by 90-95%. The dual antigen vaccine was equally effective against both variants of the SARS CoV-2 virus.

https://finance.yahoo.com/news/celsion-corporation-highlights-progress-dna-123000113.html

Vaxart: Positive Top-line Phase II Data for COVID-19 Pill Vaccine

 Study met primary safety and secondary immunogenicity endpoints 

 Boosted serum neutralizing antibodies in both naive and previously mRNA vaccinated subjects 

 Elicited cross-reactive mucosal responses in approximately 50% of subjects 

 Company to host conference call at 8:30 a.m. ET today 

The Vaxart senior management team will host a conference call today, beginning at 8:30 a.m. ET.

The conference call can be accessed using the following information:
Webcast: Click here
Date: Thursday, September 1, 2022 – 8:30 a.m. ET
Domestic: 877-407-0832
International: 201-689-8433
Conference ID: 13732510

Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.

https://finance.yahoo.com/news/vaxart-announces-positive-top-line-103000580.html

U.S. Physical Therapy Announces Acquisition Of Six-Clinic Physical Therapy Practice

 U.S. Physical Therapy, Inc. ("USPH" or the "Company") (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced an acquisition of a six-clinic physical therapy practice. The clinics are located in West Virginia and Pennsylvania.

USPH acquired 70% of the equity interests of the physical therapy practice with the practice’s founder and owners retaining 30%. The purchase price for the 70% equity interest was approximately $3.5 million. The business generates more than $2.5 million in annual revenue and has approximately 26,000 patient visits per year.

https://finance.yahoo.com/news/u-physical-therapy-announces-acquisition-113000578.html

Novo Nordisk to acquire Forma Therapeutics in $1.1. bln deal

 Danish drugmaker Novo Nordisk has agreed to buy Forma Therapeutics in a deal valued at $1.1 billion to expand its blood disorders portfolio, the companies said on Thursday.

"We have an ambition to build a leading portfolio with standalone and combination treatments to tackle the complications and underlying causes of sickle cell disease," Novo Nordisk said in a statement.

Novo Nordisk, best known for its diabetes drugs, said it would pay 20 dollar per share, which is a premium of 92% to the U.S. company's volume-weighted average price per share over the past 30 days.

The Danish group said it expected the deal, which had been unanimously approved by Forma Therapeutic's board, to close in the fourth quarter and it would not impact Novo Nordisk's full-year guidance

https://finance.yahoo.com/news/1-novo-nordisk-acquire-forma-123126788.html

China Puts Megacity Chengdu Under Lockdown As Zero-Covid Intensifies

 Asian stocks tumbled after China announced the metropolis of Chengdu would lock down its 21 million residents as authorities battled a new Covid-19 outbreak.

In China's Western region, officials in Chengdu launched massive Covid testing and requested residents to abide by "stay home in principle" from 6 pm on Thursday. The new measure allows one person per household the ability to procure essential items at places like supermarkets. 

"The current state of epidemic control is abnormal, complex, and grim," officials said, adding the lockdown aims to "decisively arrest the spread of the outbreak and guarantee the health of all citizens."

Chengdu is the biggest city to shut down since Shanghai's lockdown earlier this year. The move to lock down Chengdu will generate even more macro instability for the world's second-largest economy. It accounts for 1.7% of the national economy and is one of southwestern China's most important manufacturing hubs. 

As the capital of Sichuan province -- the 6th-largest province in terms of annual GDP -- the metro area is home to 96 listed companies in the automobile, aerospace, IT, machinery, and pharmaceutical industries. 

Automakers, including Toyota Motor Corp. and VW China. Foxconn Technology Group, the world's largest assembler of Apple Inc.'s iPhones and other devices. All have manufacturing facilities in the city. 

The lockdown was unexpected and caught investors off guard: Hong Kong's Hang Seng Index slumped almost 2%, and CSI 300 Index dropped by nearly 1% to its lowest in three months. 

Some US-listed Chinese stocks declined on the lockdown news. Alibaba traded 2% lower in the US premarket, while EV stocks such as Nio, XPeng, and Li Auto were down 3.4%, 3.1%, and 2.2%, respectively. 

A spillover of pessimism from China leaked into European luxury stocks after HSBC analyst Erwan Rambourg downgraded LVMH, Hermes, Richemont, and Swatch to a "hold" from "buy." Rambourg wrote in a note he was more cautious about the short-term industry outlook, and valuation at these levels didn't make sense. 

Analyst commentary (provided by Bloomberg) was overwhelmingly negative due to the uncertainty zero-Covid produces for the Chinese economy.

Bloomberg Intelligence, (Marvin Chen) 

  • "China's Covid-zero policy will continue to be a risk for markets and sporadic lockdowns mean any reopening recovery will likely be a bumpy one" 
  • "Local governments may ramp up efforts to contain rising Covid cases ahead of the 20th party congress" 

Union Bancaire Privee, (Vey-Sern Ling) 

  • Sporadic Covid-19 lockdowns such as this will pressure already-weak economic conditions in China but we do not expect the Covid-zero policy to shift substantially ahead of the 20th party congress in October" 

AutoML Capital, (Rebecca Lim) 

  • "This worsens the worry of China's economic slowdown, deepening of property crisis and even contagious to banking crisis if bad-loan continues" 
  • The "stringent zero-Covid measures have been enforced for more than 2 years and the wider economic environment will have a bigger impact"

All residents in the southwestern Chinese city will be confined to their homes until they test negative for Covid. There was no guidance from officials on how long the lockdown will persist. 

Also, in the Nanshan district in Shenzhen, tighter Covid measures beginning today through Sunday will close indoor public places, including cinemas, gyms, and bars, and halt in-person tutoring services to contain an outbreak. 

New lockdowns will pressure Beijing's economic planners as the economy slips into the abyss as a worsening property market slowdown is causing turmoil among developers. 

China's playbook to unleash stimulus primarily focused on infrastructure spending might not be enough to counter Covid lockdowns and a property market slump. 

https://www.zerohedge.com/markets/china-puts-megacity-chengdu-under-lockdown-zero-covid-intensifies